8-K: Zymeworks Announces Third Quarter 2024 Financial Results and Corporate Update

Zymeworks reported its Q3 2024 financial results, highlighted by a first patient dosed in a Phase 1 trial for ZW171 and the completion of an initial $30 million share repurchase program.

Summary

• Zymeworks announced its financial results for the three and nine months ended September 30, 2024, along with a corporate update.
• The company reported $45.3 million in revenue for the nine months ended September 30, 2024, compared to $59.1 million for the same period in 2023.
• Research and development expenses were $97.6 million for the nine months ended September 30, 2024, a decrease from $118.1 million in the same period of 2023.
• General and administrative expenses decreased to $45.3 million for the nine months ended September 30, 2024, from $55.6 million in the same period of 2023.
• Zymeworks recorded a non-cash impairment charge of $17.3 million due to discontinuing the zanidatamab zovodotin clinical development program.
• The net loss for the nine months ended September 30, 2024, was $99.2 million, compared to a $104.2 million loss for the same period in 2023.
• As of September 30, 2024, Zymeworks had $374.9 million in cash resources, which, combined with anticipated regulatory milestone payments, is expected to fund operations into the second half of 2027.
• The company completed the initial $30 million of its share repurchase program, buying back 2,545,402 shares at an average price of $11.79 per share as of October 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline and a strong cash position, the decrease in revenue and the impairment charge temper the overall sentiment. The company is making progress, but there are financial challenges.

Positives

• The first patient was dosed in the Phase 1 trial for ZW171, marking a significant milestone.
• The company has a strong cash position of $374.9 million, providing a cash runway into the second half of 2027.
• The share repurchase program was completed, returning value to shareholders.
• Preclinical data for ZW220 and ZW251 showed promising results.
• Zanidatamab continues to progress with positive data presented by Jazz Pharmaceuticals.
• The company is expanding its focus to new modalities and therapeutic areas.
• Net loss decreased compared to the same period in 2023.

Negatives

• Revenue decreased to $45.3 million for the nine months ended September 30, 2024, compared to $59.1 million for the same period in 2023.
• The company recorded a $17.3 million non-cash impairment charge related to the zanidatamab zovodotin program.
• Research and development expenses decreased, but this was partially due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.

Risks

• Clinical trials may not demonstrate the safety and efficacy of product candidates.
• Regulatory approvals may be delayed or not received.
• The company may not achieve milestones or receive additional payments under collaborations.
• The company's assumptions regarding its financial condition and cash runway may be incorrect.
• The company may be unable to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Zymeworks expects its existing cash resources, combined with anticipated regulatory milestone payments, to fund planned operations into the second half of 2027. The company also anticipates submitting INDs for ZW220 in the first half of 2025 and for ZW251 in the second half of 2025.

Management Comments

• Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, stated that 2024 has been a pivotal year with several significant firsts across the pipeline.
• Mr. Galbraith highlighted the potential for the first United States approval of zanidatamab in second-line biliary tract cancer.
• Mr. Galbraith also mentioned the dosing of the first patient in the Phase 1 study for ZW171.
• Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks, expressed excitement about the preclinical data presented at scientific conferences.

Industry Context

This announcement comes as the biotechnology industry continues to focus on developing novel therapies for difficult-to-treat cancers. Zymeworks' progress with its pipeline, particularly the advancement of ZW171 into Phase 1 trials and the continued development of zanidatamab by Jazz Pharmaceuticals, positions the company as a key player in the field of biotherapeutics. The company's focus on antibody-drug conjugates and multispecific antibodies aligns with current industry trends.

Comparison to Industry Standards

• Zymeworks' cash runway into 2H 2027 is relatively strong compared to many other clinical-stage biotech companies, which often face funding challenges.
• The company's focus on bispecific antibodies and ADCs is in line with industry trends, with companies like Regeneron and Seagen also heavily invested in these areas.
• The median progression-free survival (mPFS) of 15.2 months for zanidatamab in combination with chemotherapy for HER2-positive metastatic GEA is competitive with other treatments in this space, such as trastuzumab-based regimens.
• The 91% confirmed objective response rate (cORR) for zanidatamab plus chemotherapy in metastatic colorectal cancer is also very promising, comparing favorably to standard chemotherapy regimens.
• The company's share repurchase program is a positive sign for investors, indicating confidence in the company's future prospects, similar to other companies that have initiated buyback programs to enhance shareholder value.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the share repurchase program and the company's financial performance.
• Employees may be affected by the company's strategic shifts and R&D focus.
• Patients with difficult-to-treat cancers stand to benefit from the development of new therapies.
• Partners like Jazz and BeiGene will be impacted by the progress of zanidatamab and other collaborations.

Next Steps

• Zymeworks will host an in-person and virtual R&D day on December 12, 2024.
• The company expects to submit INDs for ZW220 in the first half of 2025 and for ZW251 in the second half of 2025.
• The company will continue to recruit patients for the Phase 1 studies of ZW171 and ZW191.
• Zymeworks will continue to advance its early-stage assets into the clinic and expand its focus on new modalities and therapeutic areas.

Key Dates

Keywords

Zymeworks, biotherapeutics, cancer, clinical trials, zanidatamab, ZW171, ZW220, ZW251, antibody-drug conjugates, bispecific antibodies, share repurchase, financial results, milestone payments